Meenhard Herlyn
Impact in
- Oncology top 0.02%
- Cancer Cells and Metastasis
- Cutaneous Melanoma Detection and Management
- Cancer Immunotherapy and Biomarkers
- Immunology and Allergy top 0.05%
- Cell Adhesion Molecules Research
Papers in
- Oncology 255
- Cancer Cells and Metastasis 79
- Cutaneous Melanoma Detection and Management 52
- Immunology 159
- Immunotherapy and Immune Responses 114
- Co-authors
- Hilary Koprowski (73 shared papers)Zenon Steplewski (36 shared papers)Dorothee Herlyn (32 shared papers)Keiran S.M. Smalley (33 shared papers)David E. Elder (29 shared papers)Kapaettu Satyamoorthy (30 shared papers)Ulrich Rodeck (29 shared papers)Nikolas K. Haass (21 shared papers)
- Journals
- Journal of Investigative Dermatology (35 papers)Cancer Research (31 papers)Oncogene (21 papers)Pigment Cell & Melanoma Research (19 papers)Clinical Cancer Research (16 papers)
- Partner nations
- United StatesGermanyAustralia
In The Last Decade
Meenhard Herlyn
648 papers receiving 58.7k citations
Meenhard Herlyn's Hit Papers
Peers
Comparison fields: 5 of 169
- Oncology 22.1k
- Immunology and Allergy 4.2k
- Cancer Research 8.9k
- Immunology 11.8k
- Molecular Biology 35.1k
Countries citing papers authored by Meenhard Herlyn
This map shows the geographic impact of Meenhard Herlyn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meenhard Herlyn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meenhard Herlyn more than expected).
Fields of papers citing papers by Meenhard Herlyn
This network shows the impact of papers produced by Meenhard Herlyn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meenhard Herlyn. The network helps show where Meenhard Herlyn may publish in the future.
Co-authors
The 25 scholars most cited alongside Meenhard Herlyn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 659 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response Hit paper breakdown → | 2018 | 2378 |
| 2 | Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions Hit paper breakdown → | 2005 | 1706 |
| 3 | Colorectal carcinoma antigens detected by hybridoma antibodies Hit paper breakdown → | 1979 | 1153 |
| 4 | Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Hit paper breakdown → | 2008 | 1128 |
| 5 | A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas Hit paper breakdown → | 2005 | 1082 |
| 6 | Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K Hit paper breakdown → | 2010 | 1064 |
| 7 | A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade Hit paper breakdown → | 2018 | 1015 |
| 8 | A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth Hit paper breakdown → | 2010 | 986 |
| 9 | BRAF and RAS mutations in human lung cancer and melanoma. Hit paper breakdown → | 2002 | 890 |
| 10 | High-throughput oncogene mutation profiling in human cancer Hit paper breakdown → | 2007 | 862 |
| 11 | Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance Hit paper breakdown → | 2017 | 854 |
| 12 | Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Hit paper breakdown → | 1990 | 704 |
| 13 | Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Hit paper breakdown → | 1979 | 575 |
| 14 | Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells Hit paper breakdown → | 2013 | 567 |
| 15 | Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy Hit paper breakdown → | 2017 | 537 |
| 16 | Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma Hit paper breakdown → | 2018 | 532 |
| 17 | Specific Antigen in Serum of Patients with Colon Carcinoma Hit paper breakdown → | 1981 | 507 |
| 18 | 2003 | 503 | |
| 19 | Melanoma Hit paper breakdown → | 2015 | 497 |
| 20 | Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids Hit paper breakdown → | 2017 | 484 |
About Meenhard Herlyn
Meenhard Herlyn is a scholar working on Oncology, Immunology, Molecular Biology, Immunology and Allergy and Cell Biology, having authored 659 papers that have together received 60.8k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (153 papers), Immunotherapy and Immune Responses (114 papers), Monoclonal and Polyclonal Antibodies Research (91 papers), Cell Adhesion Molecules Research (81 papers), Cancer Cells and Metastasis (79 papers), melanin and skin pigmentation (57 papers), Cutaneous Melanoma Detection and Management (52 papers) and Glycosylation and Glycoproteins Research (48 papers). The work is most often cited by research in Oncology (22.1k citations), Immunology and Allergy (4.2k citations), Cancer Research (8.9k citations), Immunology (11.8k citations) and Molecular Biology (35.1k citations). Meenhard Herlyn has collaborated with scholars based in United States, Germany and Australia. Frequent co-authors include Hilary Koprowski, Zenon Steplewski, Dorothee Herlyn, Keiran S.M. Smalley, David E. Elder, Kapaettu Satyamoorthy, Ulrich Rodeck, Nikolas K. Haass, Thomas Bogenrieder and Patricia A. Brafford. Their work appears in journals such as Journal of Investigative Dermatology, Cancer Research, Oncogene, Pigment Cell & Melanoma Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.